CN106998692B - Mk2抑制剂和其用途 - Google Patents

Mk2抑制剂和其用途 Download PDF

Info

Publication number
CN106998692B
CN106998692B CN201580058026.4A CN201580058026A CN106998692B CN 106998692 B CN106998692 B CN 106998692B CN 201580058026 A CN201580058026 A CN 201580058026A CN 106998692 B CN106998692 B CN 106998692B
Authority
CN
China
Prior art keywords
disease
disorder
mmol
certain embodiments
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201580058026.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN106998692A (zh
Inventor
马修·戴维·亚历山大
克劳迪奥·丘瓦基
约翰·马罗那
约瑟夫·约翰·麦克唐纳
易科·尼
牛德强
拉塞尔·C·彼得
尤斯温德·辛格
基塔里·帕巴
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Celgene Avilomics Research Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Avilomics Research Inc filed Critical Celgene Avilomics Research Inc
Publication of CN106998692A publication Critical patent/CN106998692A/zh
Application granted granted Critical
Publication of CN106998692B publication Critical patent/CN106998692B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Enzymes And Modification Thereof (AREA)
CN201580058026.4A 2014-09-17 2015-09-16 Mk2抑制剂和其用途 Active CN106998692B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462051788P 2014-09-17 2014-09-17
US62/051,788 2014-09-17
US201562199927P 2015-07-31 2015-07-31
US62/199,927 2015-07-31
PCT/US2015/050495 WO2016044463A2 (en) 2014-09-17 2015-09-16 Mk2 inhibitors and uses thereof

Publications (2)

Publication Number Publication Date
CN106998692A CN106998692A (zh) 2017-08-01
CN106998692B true CN106998692B (zh) 2020-09-08

Family

ID=55454109

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580058026.4A Active CN106998692B (zh) 2014-09-17 2015-09-16 Mk2抑制剂和其用途

Country Status (30)

Country Link
US (5) US9458175B2 (OSRAM)
EP (2) EP3193611B1 (OSRAM)
JP (3) JP6556225B2 (OSRAM)
KR (1) KR102457848B1 (OSRAM)
CN (1) CN106998692B (OSRAM)
AU (1) AU2015317741B2 (OSRAM)
BR (1) BR112017005266B1 (OSRAM)
CA (1) CA2961607C (OSRAM)
CL (1) CL2017000576A1 (OSRAM)
CO (1) CO2017003279A2 (OSRAM)
CY (1) CY1124215T1 (OSRAM)
DK (1) DK3193611T3 (OSRAM)
EA (1) EA037299B1 (OSRAM)
EC (1) ECSP17023281A (OSRAM)
ES (1) ES2874561T3 (OSRAM)
HR (1) HRP20210529T1 (OSRAM)
HU (1) HUE054347T2 (OSRAM)
IL (1) IL251051B (OSRAM)
LT (1) LT3193611T (OSRAM)
MA (1) MA40534B1 (OSRAM)
MX (2) MX373341B (OSRAM)
PL (1) PL3193611T3 (OSRAM)
PT (1) PT3193611T (OSRAM)
RS (1) RS62017B1 (OSRAM)
SA (1) SA517381115B1 (OSRAM)
SG (2) SG11201701861RA (OSRAM)
SI (1) SI3193611T1 (OSRAM)
SM (1) SMT202100311T1 (OSRAM)
TW (1) TWI744217B (OSRAM)
WO (1) WO2016044463A2 (OSRAM)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210091832A (ko) 2013-03-15 2021-07-22 셀젠 카르 엘엘씨 Mk2 억제제 및 이의 용도
AU2015317741B2 (en) 2014-09-17 2020-01-16 Bristol-Myers Squibb Company MK2 inhibitors and uses thereof
CN106632077B (zh) * 2016-10-10 2019-01-22 上海再启生物技术有限公司 一种2-氨基-4-溴嘧啶的制备方法
JP7282039B2 (ja) * 2017-03-16 2023-05-26 セルジーン シーエーアール エルエルシー Ｍｋ２阻害剤、その合成、およびそれに至るまでの中間体
US10882867B2 (en) * 2017-03-16 2021-01-05 Celgene Car Llc Forms and compositions of a MK2 inhibitor
EP3596084A4 (en) * 2017-03-16 2020-12-23 Celgene CAR LLC 9,10,11,12-TETRAHYDRO-8H- [1,4] DIAZEPINO [5 ', 6': 4,5] THIÉNO [3,2-F] QUINOLIN-8-ONE COMPOUNDS AND THEIR USES
JP7200120B2 (ja) * 2017-03-16 2023-01-06 セルジーン シーエーアール エルエルシー Ｍｋ２阻害剤として有用なヘテロアリール化合物
WO2018170201A1 (en) 2017-03-16 2018-09-20 Celgene Car Llc Deuterated analogs of mk2 inhibitors and uses thereof
CN107058259A (zh) * 2017-05-18 2017-08-18 南京中医药大学 分子标志物mk2基因及其应用
CA3114883A1 (en) * 2018-10-02 2020-04-09 Disc Medicine, Inc. Matriptase 2 inhibitors and uses thereof
US20220251105A1 (en) * 2019-05-17 2022-08-11 Celgene Car Llc Methods of treating a mk2-mediated disorder
CN115515588A (zh) 2020-02-14 2022-12-23 萨克生物研究学院 大环ulk1/2抑制剂
AU2021218740A1 (en) * 2020-02-14 2022-09-22 Salk Institute For Biological Studies Mono and combination therapies with ULK1/2 inhibitors
EP4114411A4 (en) * 2020-03-02 2024-04-24 Washington University Compositions and methods for the treatment of pancreatic cancer
EP4185382A4 (en) * 2020-07-24 2024-09-04 Bristol-Myers Squibb Company Methods of treating acute respiratory disorders
CA3201774A1 (en) * 2020-11-12 2022-05-19 Akttyva Therapeutics, Inc. Mk2 activating compounds for use in treating vascular leak and endothelial barrier disorders
TW202246282A (zh) 2021-02-01 2022-12-01 美商西建公司 Ｍｋ２抑制劑、其合成及其中間體
EP4079855A1 (en) * 2021-04-20 2022-10-26 Eberhard Karls Universität Tübingen Medizinische Fakultät Compound and method for the prophylaxis and treatment of leukemia
TW202328141A (zh) * 2021-08-27 2023-07-16 大陸商瑞石生物醫藥有限公司 喹啉并呋喃衍生物及其用途
WO2023134764A1 (zh) 2022-01-14 2023-07-20 上海翰森生物医药科技有限公司 含吡啶多环类衍生物、其制备方法和应用
WO2024044731A1 (en) * 2022-08-26 2024-02-29 Matchpoint Therapeutics Inc. Diazepino-thieno-quinoxaline compounds and their use in therapy
CN120390642A (zh) * 2022-10-27 2025-07-29 百时美施贵宝公司 Mk2抑制剂及其用途
KR20250139398A (ko) * 2023-02-07 2025-09-23 셀진 코포레이션 Mk2 키나제의 분해제로서 유용한 화합물 및 조성물
WO2024229401A2 (en) * 2023-05-04 2024-11-07 Matchpoint Therapeutics Inc. Diazepino-thieno-quinoxaline compounds and their use in therapy
CN121368484A (zh) * 2023-06-26 2026-01-20 深圳信立泰药业股份有限公司 一种mk2抑制剂在制备预防和/或治疗疾病药物中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011153553A2 (en) * 2010-06-04 2011-12-08 The Regents Of The University Of California Methods and compositions for kinase inhibition

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5015778A (en) 1989-12-18 1991-05-14 The Dow Chemical Company Catalytic method to produce hydroxy substituted arylophenones
CN1087725C (zh) 1994-03-25 2002-07-17 同位素技术有限公司 用氘代方法增强药物效果
US5441946A (en) 1994-04-14 1995-08-15 Rhone-Poulenc-Rorer Pharmaceuticals, Inc. Phosphonate derivatives of lipophilic amines
GB9828511D0 (en) * 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
US6861440B2 (en) * 2001-10-26 2005-03-01 Hoffmann-La Roche Inc. DPP IV inhibitors
TW200413273A (en) 2002-11-15 2004-08-01 Wako Pure Chem Ind Ltd Heavy hydrogenation method of heterocyclic rings
AU2003297431A1 (en) 2002-12-20 2004-07-22 Pharmacia Corporation Mitogen activated protein kinase-activated protein kinase-2 inhibiting compounds
WO2005020921A2 (en) 2003-08-29 2005-03-10 Exelixis, Inc. C-kit modulators and methods of use
WO2005105814A1 (en) 2004-04-28 2005-11-10 Incyte Corporation Tetracyclic inhibitors of janus kinases
MX2007009388A (es) 2005-02-04 2007-09-25 Senomyx Inc Compuestos que comprenden porciones heteroarilo unidas y su uso como modificadores del sabor unami, saborizantes y mejoradores del sabor para composiciones comestibles.
EP1849781A1 (en) 2006-04-28 2007-10-31 Laboratorios del Dr. Esteve S.A. Substituted 3-Amino-4-hydroxy pyrrolidines compounds, their preparation and use as medicaments
EP2223925A1 (en) 2006-10-09 2010-09-01 Takeda Pharmaceutical Company Limited Kinase inhibitors
AU2008277676A1 (en) 2007-07-16 2009-01-22 Novartis Ag Heterocyclic compounds useful as MK2 inhibitors
JP2011500727A (ja) 2007-10-22 2011-01-06 シェーリング コーポレイション Ｇｐｒ１１９の活性のモジュレーターとしての二環式ヘテロ環誘導体およびその使用
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
NZ603525A (en) 2008-06-27 2015-02-27 Celgene Avilomics Res Inc Pyrimidine based compound and uses thereof
WO2010048149A2 (en) 2008-10-20 2010-04-29 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
US20110269744A1 (en) * 2010-03-12 2011-11-03 Astellas Pharma Inc. Benzazepine Compound
EP2508511A1 (en) * 2011-04-07 2012-10-10 Laboratoire Biodim Inhibitors of viral replication, their process of preparation and their therapeutical uses
EP2511273B8 (en) * 2011-04-15 2019-06-26 Hivih Inhibitors of viral replication, their process of preparation and their therapeutical uses
CN104136576B (zh) 2012-02-22 2020-10-16 默克专利股份有限公司 液晶介质
EP2832734A4 (en) * 2012-03-28 2015-08-26 Takeda Pharmaceutical HETEROCYCLIC COMPOUND
TW201406758A (zh) * 2012-06-28 2014-02-16 Daiichi Sankyo Co Ltd 三環性化合物
HK1210696A1 (en) * 2012-07-11 2016-05-06 Nimbus Iris, Inc. Irak inhibitors and uses thereof
US20150269216A1 (en) * 2012-09-24 2015-09-24 Claremont Speede Mobile sender controlled data access and data deletion method and system
TW201417817A (zh) * 2012-09-25 2014-05-16 Daiichi Sankyo Co Ltd Ｇｓｋ３抑制劑與抗ｄｒ５抗體之組合
WO2014139144A1 (en) 2013-03-15 2014-09-18 Agios Pharmaceuticals, Inc. Therapeutic compounds and compositions
KR20210091832A (ko) 2013-03-15 2021-07-22 셀젠 카르 엘엘씨 Mk2 억제제 및 이의 용도
WO2015050957A2 (en) 2013-10-02 2015-04-09 Treatments For Systemic Lupus Erythematosus Treatments for systemic lupus erythematosus
US10512651B2 (en) 2014-08-25 2019-12-24 Stc.Unm Inhibition of MK2 in the treatment of cancer
AU2015317741B2 (en) 2014-09-17 2020-01-16 Bristol-Myers Squibb Company MK2 inhibitors and uses thereof
US10087225B2 (en) 2015-01-08 2018-10-02 Moerae Matrix, Inc. Formulation of MK2 inhibitor peptides
JP7282039B2 (ja) 2017-03-16 2023-05-26 セルジーン シーエーアール エルエルシー Ｍｋ２阻害剤、その合成、およびそれに至るまでの中間体
JP7200120B2 (ja) 2017-03-16 2023-01-06 セルジーン シーエーアール エルエルシー Ｍｋ２阻害剤として有用なヘテロアリール化合物
EP3596084A4 (en) 2017-03-16 2020-12-23 Celgene CAR LLC 9,10,11,12-TETRAHYDRO-8H- [1,4] DIAZEPINO [5 ', 6': 4,5] THIÉNO [3,2-F] QUINOLIN-8-ONE COMPOUNDS AND THEIR USES
US10882867B2 (en) 2017-03-16 2021-01-05 Celgene Car Llc Forms and compositions of a MK2 inhibitor
WO2018170201A1 (en) 2017-03-16 2018-09-20 Celgene Car Llc Deuterated analogs of mk2 inhibitors and uses thereof
US20220251105A1 (en) 2019-05-17 2022-08-11 Celgene Car Llc Methods of treating a mk2-mediated disorder
EP4185382A4 (en) 2020-07-24 2024-09-04 Bristol-Myers Squibb Company Methods of treating acute respiratory disorders

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011153553A2 (en) * 2010-06-04 2011-12-08 The Regents Of The University Of California Methods and compositions for kinase inhibition

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Benzothiophene inhibitors of MK2. Part 2:Improvements in kinase selectivity and cell potency;ANDERSON et aL;《Bioorganic & Medicinal Chemistry Letters》;20091231;第19卷;第4882-4884页 *
Binding Affinity Prediction for Ligands and Receptors Forming Tautomers and Ionization Species: Inhibition of Mitogen-Activated Protein Kinase-Activated Protein Kinase 2 (MK2);Senthil Natesan et al;《Journal of Medicinal Chemistry》;20120126;第55卷;第2035-2047页 *

Also Published As

Publication number Publication date
JP7375072B2 (ja) 2023-11-07
TW201617351A (zh) 2016-05-16
JP6556225B2 (ja) 2019-08-07
US9458175B2 (en) 2016-10-04
SG10201902326XA (en) 2019-04-29
JP2017529367A (ja) 2017-10-05
WO2016044463A3 (en) 2016-09-01
NZ730603A (en) 2024-02-23
CN106998692A (zh) 2017-08-01
PT3193611T (pt) 2021-05-28
BR112017005266B1 (pt) 2022-11-01
JP2022078315A (ja) 2022-05-24
KR20170063734A (ko) 2017-06-08
US10253040B1 (en) 2019-04-09
EA037299B1 (ru) 2021-03-05
EP3193611B1 (en) 2021-03-24
CA2961607A1 (en) 2016-03-24
US20160075720A1 (en) 2016-03-17
AU2015317741A1 (en) 2017-04-20
MX373341B (es) 2020-05-26
US20190375762A1 (en) 2019-12-12
US11584757B2 (en) 2023-02-21
DK3193611T3 (da) 2021-05-10
SG11201701861RA (en) 2017-04-27
EP3912981A1 (en) 2021-11-24
EP3193611A4 (en) 2018-02-28
US9790235B2 (en) 2017-10-17
KR102457848B1 (ko) 2022-10-25
CA2961607C (en) 2023-03-28
SI3193611T1 (sl) 2021-08-31
SMT202100311T1 (it) 2021-07-12
JP2019194236A (ja) 2019-11-07
LT3193611T (lt) 2021-08-25
ES2874561T3 (es) 2021-11-05
HRP20210529T1 (hr) 2021-08-06
US10577380B2 (en) 2020-03-03
CL2017000576A1 (es) 2017-12-01
MX2017003359A (es) 2017-11-22
CY1124215T1 (el) 2022-05-27
IL251051A0 (en) 2017-04-30
HUE054347T2 (hu) 2021-08-30
MX2020005213A (es) 2020-08-20
EP3193611A2 (en) 2017-07-26
EA201790380A1 (ru) 2017-08-31
SA517381115B1 (ar) 2021-03-09
WO2016044463A2 (en) 2016-03-24
MA40534B1 (fr) 2021-04-30
MA40534A (fr) 2016-03-24
ECSP17023281A (es) 2017-06-30
AU2015317741B2 (en) 2020-01-16
RS62017B1 (sr) 2021-07-30
US20210053984A1 (en) 2021-02-25
PL3193611T3 (pl) 2021-10-04
US20170114073A1 (en) 2017-04-27
CO2017003279A2 (es) 2017-09-29
BR112017005266A2 (pt) 2017-12-12
IL251051B (en) 2019-11-28
TWI744217B (zh) 2021-11-01

Similar Documents

Publication Publication Date Title
JP7375072B2 (ja) Ｍｋ２阻害剤およびその使用
JP6554507B2 (ja) ヘテロアリール化合物およびそれらの使用
KR101712576B1 (ko) Ａｔｒ 키나제의 억제제로서 유용한 화합물
EP2766360B1 (en) Soluble guanylate cyclase activators
EP3872075A1 (en) Intermediates and processes for the preparation of biaryl compounds
WO2016090079A1 (en) Heteroaryl compounds and uses thereof
EP4608401A2 (en) Mk2 inhibitors and uses thereof
HK1241225B (en) Mk2 inhibitors and uses thereof
HK1241225A1 (en) Mk2 inhibitors and uses thereof
CN117940433A (zh) 喹啉并呋喃衍生物及其用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20230619

Address after: new jersey

Patentee after: BRISTOL-MYERS SQUIBB Co.

Address before: Bermuda Hamilton

Patentee before: CELGENE AVILOMICS RESEARCH, Inc.